“We are pleased to be working with such a successful mid-size biotech company to advance and strengthen their robust portfolio of innovative therapies,” said Dr. Stephan Kutzer, head of Lonza Biopharmaceuticals. “Supporting Medarex’s immediate and long-term needs with our expertise in mammalian cell culture and antibody drug conjugates is both exciting and rewarding.”
Medarex’s biologics portfolio is focused on treating oncology and immunology therapeutic indications with ten antibody programs in Phase III to Phase I development. Under the terms of the agreement, Lonza may be supporting a portion of the Medarex product pipeline.